Comparative Effectiveness of Long-Acting Risperidone in New Zealand: A Report of Resource Utilization and Costs in a 12-Month Mirror-Image Analysis

Author： Carswell Christopher   Wheeler Amanda   Vanderpyl Jane  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.30, Iss.11, 2010-11, pp. : 777-787

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness Model Of Long-Acting Risperidone in Schizophrenia in the US

By Edwards Natalie C.  

PharmacoEconomics, Vol. 23, Iss. 3, 2005-01 ,pp. : 299-314

Adis International

Access to resources Recommend Favorite

Spotlight on Long-Acting Risperidone in Schizophrenia

By Tracy Swainston Harrison   Karen L. Goa  

American Journal of Drug Delivery, Vol. 2, Iss. 3, 2004-01 ,pp. : 207-210

Adis International

Access to resources Recommend Favorite

Treatment with long-acting risperidone injection is not associated with reductions in hospital stay or resource use

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 513, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Long-acting risperidone adds value in schizophrenia

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 443, 2003-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Long-Acting Risperidone: A Review of Its Use in Schizophrenia

By Tracy Swainston Harrison   Goa K.L.  

CNS Drugs, Vol. 18, Iss. 2, 2004-01 ,pp. : 113-132

Adis International

Access to resources Recommend Favorite